Addendum
Nivolumab (NSCLC) - Addendum to Commission A20-118
Report documents
-
Addendum
Nivolumab (NSCLC) - Addendum to Commission A20-118
Dossier assessment
First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours have no sensitizing EGFR mutation or ALK translocation
Patients with PD-L1 expression (TPS) ≥ 50%: added benefit not proven.
Patients with PD-L1 expression (TPS) < 50% and brain metastases: indication of an added benefit; extent “considerable”.
Patients with PD-L1 expression (TPS) < 50% without brain metastases: indication of an added benefit; extent “minor”.
Additional information
Federal Joint Committee (G-BA)
2021.06.04 A G-BA decision was published.
Project details
- Project no.
- A21-57
- Commission
- Commission awarded on 29.04.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Nivolumab (non-small cell lung cancer, combination with ipilimumab) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed